AlphAIAlphAI — Financial news for AI agents
investing.comOCT 82 min read$NRXS

Neuraxis CFO Timothy Henrichs buys $9,375 in company stock

Neuraxis CFO Timothy Henrichs bought 1,937 shares of Neuraxis (NRXS) stock at $4.84 per share, totaling $9,375. The company reported a 116% revenue increase to $1.928M in Q2 2026, but a wider loss of $0.19 per share. NRXS shares are up 40% since the purchase, with a 116% return over the past year.

Original reporting
investing.com
Published Oct 8, 2026, 10:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 5:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$NRXS
Neutral
medium confidence
Mentioned
$NRXS
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NRXSNeutralLow
01

Why it matters

The CFO's insider purchase adds a modest positive nuance to the recent earnings miss.

02

Market read

Insider buying provides a small bullish cue amid mixed earnings results.

03

What to watch

The CFO's buy could be part of a pre-arranged equity plan, diluting its signaling value.

Relevance 4/10Novelty 5/10Timing: today

Background

NRXS reported Q2 2026 earnings with strong revenue growth but a wider-than-expected loss.

Company-level read

Ticker impact

$NRXSNeutralMedium confidence
Context

CFO Timothy Henrichs purchased 1,937 shares of NRXS at $4.84 per share, a $9,375 insider buy.

Expected impact

likely slight upward pressure as market views the buy as confidence signal

Evidence & confidence

The transaction size is modest relative to market cap, but insider buying is generally viewed positively.

Market effects

Sector

Minimal impact on the broader medical device sector.

Regional

Limited to US investors tracking NRXS.

Global

None

Counterpoint

What could challenge this read

The purchase may be routine compensation rather than a strong endorsement.

Key entities

  • person
    Timothy Robert Henrichs

    Chief Financial Officer of NRXS

Read at source← All news

Related articles

SEP 16
$NRXSHighAI 8/10

NeurAxis Expands PENFS Coverage By 18 Million Lives As IB-Stim Adoption Grows; Stock Up

NeurAxis (NRXS) announced that a major national insurer expanded coverage for its PENFS therapy, adding 18 million members, bringing total coverage to 120 million. The company's IB-Stim device is FDA-cleared for pediatric abdominal pain. CEO Brian Carrico highlighted growth acceleration and plans to pursue additional insurers. NRXS stock is up 21.77% to $6.94.

rttnews.com2 min
SEP 16
$NRXSHigh

NeurAxis secures major insurer coverage for IB-Stim device

NeurAxis (NRXS) announced a major national health insurer will cover its IB-Stim device for treating abdominal pain in patients aged 8+. The coverage applies to 18M members across multiple states. The FDA-cleared device is a non-invasive neuromodulation technology. NeurAxis aims to secure coverage from more insurers and is conducting additional clinical trials. The company did not disclose the insurer's name or provide financial projections.

investing.com2 min
SEP 16
$NRXSMed

NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

NeurAxis (NRXS) announced a new medical policy coverage from a major national health insurer for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, expanding access to 18 million members. IB-Stim is FDA-cleared for treating functional abdominal pain in children and adults. The company aims to broaden payer coverage and increase commercialization, citing a strong foundation and potential for revenue growth.

globenewswire.com2 min